Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amicus Therapeutics (GB:0HF9)
LSE:0HF9
Amicus (0HF9) Share Price & Analysis
0 Followers
0HF9 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.04 - $14.57
Previous Close$10.22
Volume133.00
Average Volume (3M)847.00
Market Cap
$3.02B
Enterprise Value$3.22B
Total Cash (Recent Filing)$239.60M
Total Debt (Recent Filing)$444.49M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Aug 01, 2024EPS Estimate
-$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding296,198,963
10 Day Avg. Volume661
30 Day Avg. Volume847
Standard Deviation0.16
R-Squared0.13
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-34.44
Price to Sales (P/S)49.47
Price to Cash Flow (P/CF)-25.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.60
Enterprise Value/Gross Profit8.89
Enterprise Value/Ebitda-76.53
Forecast
1Y Price Target
$17.00Price Target Upside66.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Amicus News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceGalafold continues to surpass expectations with a beat and raise, prompting management to raise their FY24 year-over-year growth guidance to 13-17%.
Market ExpansionManagement highlights confidence in P&O opportunity with potential for growth acceleration as geographic expansion continues, therapy awareness grows, and reimbursement dynamics improve.
Regulatory ApprovalPomOp was approved by the FDA, and investors are focusing on its launch against pressure from SNY's Nexviazyme.
Bears Say
Market StabilityMajority of surveyed physicians noted their LOPD patients are either stable or improving on Myozyme/Lumizyme or Nexviazyme.
Revenue GuidanceManagement provided guidance for the first time, expecting FY24 revenue of $62-67M, which is meaningfully below prior estimate of $98.9M and consensus of $98.1M.
Sales PerformanceThe company reported Pombiliti/cipaglucosidase alfa and Opfolda/miglustat sales of $11.0M in Late-Onset Pompe Disease for 1Q24, below consensus estimate of $13.4M.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.90% Other Institutional Investors
99.10% Public Companies and
Individual Investors
0HF9 FAQ
What was Amicus Therapeutics’s price range in the past 12 months?
Amicus Therapeutics lowest share price was $9.04 and its highest was $14.57 in the past 12 months.
What is Amicus Therapeutics’s market cap?
Currently, no data Available
When is Amicus Therapeutics’s upcoming earnings report date?
Amicus Therapeutics’s upcoming earnings report date is Aug 01, 2024 which is in 5 days.
How were Amicus Therapeutics’s earnings last quarter?
Amicus Therapeutics released its earnings results on May 09, 2024. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.064 by -$0.096.
Is Amicus Therapeutics overvalued?
According to Wall Street analysts Amicus Therapeutics’s price is currently Undervalued.
Does Amicus Therapeutics pay dividends?
Amicus Therapeutics does not currently pay dividends.
What is Amicus Therapeutics’s EPS estimate?
Amicus Therapeutics’s EPS estimate is -$0.06.
How many shares outstanding does Amicus Therapeutics have?
Currently, no data Available
What happened to Amicus Therapeutics’s price movement after its last earnings report?
Amicus Therapeutics reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.064. Following the earnings report the stock price went down -8.844%.
Which hedge fund is a major shareholder of Amicus Therapeutics?
Among the largest hedge funds holding Amicus Therapeutics’s share is Perceptive Advisors LLC. It holds Amicus Therapeutics’s shares valued at 331M.
---
Amicus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (66.32% Upside)
$17.00 (66.32% Upside)
Blogger Sentiment
Bullish
GB:0HF9 Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $225.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.74%
12-Months-Change
Fundamentals
Return on Equity
-126.10%
Trailing 12-Months
Asset Growth
3.04%
Trailing 12-Months
Company Description
Amicus Therapeutics
Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.
---
0HF9 Company Deck
---
0HF9 Earnings Call
Q1 2024
0:00 / 0:00
---
0HF9 Stock 12 Month Forecast
Average Price Target
$17.00
▲(66.32% Upside)
Technical Analysis
Amicus
―
Agios Pharma
―
Sarepta Therapeutics
―
Crispr Therapeutics AG
―
Bluebird Bio
―
Best Analysts Covering 0HF9
1 Year
1 Year Success Rate
8/12 ratings generated profit
1 Year Average Return
+30.19%
upgraded a buy rating 2 months ago
Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +30.19% per trade.
---